Geron (GERN)
(Delayed Data from NSDQ)
$3.69 USD
-0.04 (-1.07%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $3.70 +0.01 (0.27%) 5:04 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.69 USD
-0.04 (-1.07%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $3.70 +0.01 (0.27%) 5:04 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
by Zacks Equity Research
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
Company News for Mar 18, 2024
by Zacks Equity Research
Companies In The Article Are: GERN, AAPL, JBL and UBER
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
by Zacks Equity Research
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Implied Volatility Surging for Geron (GERN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Geron (GERN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Techne (TECH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -6.82% and 4.44%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -12.50% and 79.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Company News for May 12, 2023
by Zacks Equity Research
Companies in The News Are: CYBR,GERN,TPR,DDS
Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of -2.70% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Geron (GERN) closed the most recent trading day at $2.30, moving -1.71% from the previous trading session.
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Protagonist (PTGX) Up on Positive Results From FRONTIER Study
by Zacks Equity Research
Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.
Intercept (ICPT) Q4 Earnings Beat, Ocaliva Sales Increase
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in Q4 due to higher revenues.
Amicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates
by Zacks Equity Research
Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 1.72% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.
Geron (GERN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Geron (GERN) closed the most recent trading day at $2.74, moving +1.48% from the previous trading session.